Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

EGFR inhibition in EGFR-mutant lung cancer cells perturbs innate immune signaling pathways in the tumor microenvironment.

Cancer science - 1 Apr 2023

Shiiya Akihiko, Noguchi Takuro, Tomaru Utano, Ariga Shin, Takashima Yuta, Ohhara Yoshihito, Taguchi Jun, Takeuchi Satoshi, Shimizu Yasushi, Kinoshita Ichiro, Koizumi Tomonobu, Matsuno Yoshihiro, Shinagawa Naofumi, Sakakibara-Konishi Jun, Dosaka-Akita Hirotoshi

Abstract excerpt

Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) elicit potent cell cycle arrest in EGFR-mutant non-small-cell lung cancer (NSCLC) cells. However, little is known about the mechanisms through which these drugs alter the tumor phenotype that contributes to the immune escape of EGFR-mutant cells. Using EGFR-mutant NSCLC cell lines and tissue samples from patients, we investigated the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to Lung Neoplasms

Share to Mutation

Share to Protein Kinase Inhibitors

Share to Signal Transduction

Share to Tumor Microenvironment

Source

Open in PubMed Open full text

Identifiers

PMID: 36529523
DOI: 10.1111/cas.15701
PMCID: PMC10067399

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 10 closest

EGFR inhibition in EGFR-mutant lung cancer cells perturbs innate immune signaling pathways in the tumor microenvironment.PMID 36529523Read ↗

Progression of EGFR-Mutant Lung Adenocarcinoma is Driven By Alveolar MacrophagesSemantic proximity Read ↗

Short-term EGFR blockade enhances immune-mediated cytotoxicity of EGFR mutant lung cancer cells: rationale for combination therapies.Semantic proximity Read ↗

Reactivation of Mutant-EGFR Degradation through Clathrin Inhibition Overcomes Resistance to EGFR Tyrosine Kinase Inhibitors.Semantic proximity Read ↗

Tumor regression mediated by oncogene withdrawal or erlotinib stimulates infiltration of inflammatory immune cells in EGFR mutant lung tumors.Semantic proximity Read ↗

CD70 is a therapeutic target upregulated in EMT-associated EGFR tyrosine kinase inhibitor resistance.Semantic proximity Read ↗

A Systematic Analysis Reveals Heterogeneous Changes in the Endocytic Activities of Cancer CellsSemantic proximity Read ↗

Targeting Immunometabolism Mediated by CD73 Pathway in EGFR-Mutated Non-small Cell Lung Cancer: A New Hope for Overcoming Immune Resistance.Semantic proximity Read ↗

A molecularly engineered lectin destroys EGFR and inhibits the growth of non-small cell lung cancerSemantic proximity Read ↗

EGFR-targeted therapy results in dramatic early lung tumor regression accompanied by imaging response and immune infiltration in EGFR mutant transgenic mouse models.Semantic proximity Read ↗

Tumor-Targeted Nanoparticles Deliver a Vitamin D-Based Drug Payload for the Treatment of EGFR Tyrosine Kinase Inhibitor-Resistant Lung Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.